---
title: "HitGen: Partner BioAge launches Phase I clinical study of novel NLRP3 inhibitor BGE-102"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257271738.md"
description: "HitGen's partner BioAgeLabs, Inc. recently launched a Phase I clinical study of the novel NLRP3 inhibitor BGE-102. This compound was obtained through screening of HitGen's DNA-encoded compound library, and HitGen will receive relevant milestone payments according to the cooperation agreement, with specific amounts not disclosed. BGE-102 is an oral small molecule NLRP3 inhibitor with a novel structure and good brain penetration, aimed at treating obesity"
datetime: "2025-09-15T01:12:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257271738.md)
  - [en](https://longbridge.com/en/news/257271738.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257271738.md)
---

# HitGen: Partner BioAge launches Phase I clinical study of novel NLRP3 inhibitor BGE-102

According to news from HitGen, the company's partner BioAgeLabs, Inc. has recently launched a Phase I clinical study of the novel and potent NLRP3 inhibitor BGE-102. The lead compound of BGE-102 was obtained through screening of HitGen's DNA-encoded compound library. According to the cooperation agreement between the two parties, HitGen will receive relevant milestone payments, the specific amount of which has not been disclosed. BGE-102 is an orally administered small molecule NLRP3 inhibitor with a novel structure, high activity, and good brain penetration, developed for the treatment of obesity

### Related Stocks

- [688222.CN](https://longbridge.com/en/quote/688222.CN.md)

## Related News & Research

- [Hidden Cost Of Financial Inaction, And How To Break The Cycle - The Decision You Make By Not Deciding](https://longbridge.com/en/news/286786034.md)
- [CXMT Revenue Surges 700% Ahead of Planned China IPO](https://longbridge.com/en/news/286807461.md)
- [The Verge’s 2026 high school graduation gift guide](https://longbridge.com/en/news/287089539.md)
- [Grown Up Group Sets June 2026 AGM to Approve Results and Share Mandate](https://longbridge.com/en/news/286990715.md)
- [20:00 ETAccro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases](https://longbridge.com/en/news/286830151.md)